Table 2.
Subtypea | Total (N = 1719) | QDU (1) OPs (n = 688) | QDU (2) OPs (n = 496) | Total OPs 1 (n = 1184) | IPs 2 (n = 535) | P value 1 vs 2 |
---|---|---|---|---|---|---|
Classical Hodgkin lymphoma | 318 (18.5) | 128 (18.6) | 88 (17.7) | 216 (18.2) | 102 (19.1) | .164 |
Nodular sclerosis, NOSb | 235 (73.9) | 96 (75.0) | 66 (75.0) | 162 (75.0) | 73 (71.6) | .045 |
Mixed cellularity, NOSc | 37 (11.6) | 16 (12.5) | 10 (11.4) | 26 (12.0) | 11 (10.8) | .135 |
Lymphocyte richd | 13 (4.1) | 5 (3.9) | 3 (3.4) | 8 (3.7) | 5 (4.9) | .140 |
Lymphocyte depletion, NOSe | 4 (1.3) | 1 (0.8) | 0 (0.0) | 1 (0.5) | 3 (2.9) | .078 |
Classical Hodgkin lymphoma, NOSf | 29 (9.1) | 10 (7.8) | 9 (10.2) | 19 (8.8) | 10 (9.8) | .156 |
Large B-cell lymphomag | 578 (33.6) | 218 (31.7) | 151 (30.4) | 369 (31.2) | 209 (39.1) | <.001 |
Follicular lymphoma, NOSh | 562 (32.7) | 250 (36.3) | 189 (38.1) | 439 (37.1) | 123 (23.0) | <.001 |
Mature nodal peripheral T-cell lymphomai | 261 (15.2) | 92 (13.4) | 68 (13.7) | 160 (13.5) | 101 (18.9) | <.001 |
Peripheral T-cell lymphoma, NOSj | 147 (56.3) | 50 (54.3) | 37 (54.4) | 87 (54.4) | 60 (59.4) | <.001 |
Angioimmunoblastic T-cell lymphomak | 77 (29.5) | 28 (30.4) | 21 (30.9) | 49 (30.6) | 28 (27.7) | .076 |
Anaplastic large cell lymphoma, ALK-negativel | 37 (14.2) | 14 (15.2) | 10 (14.7) | 24 (15.0) | 13 (12.9) | .086 |
Abbreviations: NOS not otherwise specified; ALK anaplastic lymphoma kinase. For other abbreviations, see Table 1
aThe ICD-O-3 codes of the International Classification of Diseases for Oncology, 3rd edition [32], are shown for each lymphoma subtype; b9663/3; c9652/3; d9651/3; e9653/3; f9650/3; g9680/3, 9684/3, 9735/3, 9688/3, and 9679/3 (anaplastic large B-cell lymphoma, diffuse large B-cell lymphoma associated with chronic inflammation, primary diffuse large B-cell lymphoma of the CNS, primary cutaneous DLBCL leg type, and EBV positive diffuse large B-cell lymphoma of the elderly were excluded); h9690/3; i9702/3; j9702/3; k9705/3; l9702/3